Early and Late Humoral Rejection: A Clinicopathologic Entity in Two Times

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 3229-3236

  Pefaur J ^a   Diaz P ^a   Panace, R ^a   Salinas, P ^a   Fiabane, A ^a   Quinteros, N ^a   Chea, R ^a   Naranjo, E ^a   Wurgaft, A ^a   Beltran, E ^a   Elgueta, S ^a   Wegmann, M E ^b   Gajardo, J G ^b   Contreras, L ^a  

^a HOSPITAL BARROS LUCO TRUDEAU   (Chile)

^b Instituto de Salud Pública

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4D; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DIALYSIS; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; VASCULAR DISEASE;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, CD20; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; CREATININE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 55749085077     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.123     Document Type: Article

References (102)

1. Halloran P.F., Wadgymar A., Ritchie S., et al. The significance of anti class I antibody response. Clinical and pathologic features of anticlass I mediated rejection. Transplantation 49 (1990) 85
2. Halloran P.F., Schlaut J., Solez K., et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53 (1992) 550
3. Davis C.L. Transplant: immunology and treatment of rejection. Am J Kidney Dis 43 (2004) 1116
4. Opelz G: Collaborative transplant study. 2001 CTS-K-73001
5. Monteiro F., Buelow R., Mineiro C., et al. Identification of patients at high risk of graft loss by pre- and post transplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Transplantation 63 (1997) 542
6. Sumitran-Holgersson S. HLA-Specific alloantibodies and renal graft outcome. Nephrol Dial Transplant 16 (2001) 897
7. Costa A.N., Scolari M.P., Iannelli S., et al. The presence of post transplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 63 (1997) 167
8. Jeannet M., Pinn V.W., Flax M.H., et al. Humoral antibodies in renal allotransplantation in man. N Engl J Med 338 (1970) 1813
9. Feucht H.E., Felber E., Gokeel M.J., et al. Vascular deposition of complement-split product in kidney allografts with cell Imediated rejection. Clin Exp Immunol 86 (1991) 464
10. Feucht H.E., Schnneeberger H., Hillebrand G., et al. Capillary deposition of C4d complement fragment and early graft loss. Kidney Int 43 (1993) 1933
11. Collins A.B., Schneeberger E., Pascual M., et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 10 (1999) 2208
12. Mauiyyedi S., Crespo M., Collins A.B., et al. Acute humoral rejection in kidney transplantation II. Morphology, immunopathology and pathologic classification. J Am Soc Nephrol 13 (2002) 779
13. Watschinger B., and Pascual M. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 13 (2002) 1420
14. Crespo M., Pascual M., Tolkoff-Rubin N., et al. Acute humoral rejection in renal allograft recipients. Incidence, serology and clinical characteristics. Transplantation 71 (2001) 652
15. Rotman S., Collin B., and Collins R.B. C4d deposition in allografts. Transplant Rev 19 (2005) 65
16. Talbot D., White M., Shenton B.K., et al. Flow cytometric crossmatching in renal transplantation-the long-term outcome. Transpl Immunol 3 (1995) 352
17. Iñaki Y., and Teraski P. Primary nonfunction in human cadaver kidney transplantation: evidence for hidden hyperacute rejection. Clin Transplantation 1 (1987) 125
18. Nishikawa K., and Terasaki P. Annual trends and triple therapy: 1991-2000. In: Cecka J.M., and Teraski P.I. (Eds). Clinical Transplants 2001 (2002), UCLA Immunogenetics Center, Los Angeles 247
19. Rocha P.N., Butterly D.W., Greenberg A., et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75 (2003) 1490
20. Zachary A.A., Montgomery R.A., Ratner L.E., et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76 (2003) 1519
21. Terasaki P., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 (2004) 438
22. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 3 (2003) 665
23. Michaels P.J., Fishbein M.C., and Colvin R.B. Humoral rejection of human organ transplants. Springer Semin Immunopathol 25 (2003) 119
24. Oluwole S.F., Tezuka K., Wasfie T., et al. Humoral immunity in allograft rejection. The role of cytotoxic alloantibody in hyperacute rejection and enhancement of rat cardiac allografts. Transplantation 48 (1989) 751
25. Duijvestijn A.M., and van Breda Vriesman P.J. Chronic renal allograft rejection. Selective involvement of the glomerular endothelium in humoral immune reactivity and intravascular coagulation. Transplantation 52 (1991) 195
26. Barr M.L., Cohen D.J., Benvenisty A.T., et al. Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts. Transplant Proc 25 (1993) 262
27. De Heer E., Davidoff A., van der Wal A., et al. Chronic renal allograft rejection in the rat. Transplantation-induced antibodies against basement membrane antigens. Lab Invest 70 (1994) 494
28. Regele H., Bohmig G.A., Habicht A., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 13 (2002) 2371
29. Mauiyyedi S., Pelle P., Saidman S., et al. Chronic humoral rejection: Identification of antibody mediated chronic renal allogrft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 12 (2001) 574
30. Braun W.E. Long-term renal transplantation. Recent successes and new problems. Nefrology 55 (2003) 13
31. Aita K., Yamaguchi Y., Horita S., et al. Peritubular capillaritis in early renal allograft is associated with the development of chronic rejection and chronic allograft nephropathy. Clin Transplant 19 Suppl 14 (2005) 20
32. Lobo P.J., Spencer C.E., Stevenson W.C., et al. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 59 (1995) 357
33. Palomar R., Lopez-Hoyos M., Pastor J.M., et al. Impact of HLA antibodies on transplant glomerulopathy. Transplant Proc 37 (2005) 3830
34. Bonsib S.M., Abul-Ezz S.R., Ahmad I., et al. Acute rejectionassociated tubular basement membrane defects and chronic allograft nephropathy. Kidney Int 58 (2000) 2206
35. Smith R.N., Kawai T., Boskovic S., et al. Natural history of chronic humoral rejection of renal allografts in a non human primate. Transplantation 2 Suppl 78 (2004) 167
36. Trpkov K., Campbell P., Pazderka F., et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: Analysis using the Banff grading schema. Transplantation 61 (1996) 1586
37. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria -an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3 (2003) 708
38. Bohming G., and Regele H. Diagnosis and treatment of antibodymediated kidney allograft rejection. Transpl Int 16 (2003) 773
39. Habicht A., Regele H., Exner M., et al. A case of severe C4d positive kidney allograft dysfunction in the absence of histomorphologic features of rejection. Wien Klin Wochenschr 114 (2002) 945
40. Bohming G.A., Exner M., Habicht A., et al. Capillary C4d deposition in kidney allografts: A specific marker of alloantibodydependent graft injury. J Am Soc Nephrol 13 (2002) 1091
41. Collins A.B., Scheneeberger E., Pascual M.A., et al. Complement activation in acute humoral rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 10 (1999) 2203
42. Cai J., and Terasaki P.I. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 66 (2005) 334
43. Arumugam T.V., Shiels I.A., Woodruff T.M., et al. The role of the complement system in ischemia-reperfusion injury. Shock 21 (2004) 401
44. Baldwin III W.M., Samaniego-Picota M., Kasper E.K., et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 68 (1999) 894
45. Thurman J.M., Ljubanovic D., Royer P.A., et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116 (2006) 357
46. Colvin R.B., and Smith R.N. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5 (2005) 807
47. Halloran P.F. The clinical importance of alloantibodymediated rejection. Am J Transplant 3 (2003) 639
48. Worthington J.E., Martin S., Dyer P.A., et al. An association between post transplant antibody production and renal transplant rejection. Transplant Proc 33 (2001) 475
49. Shah A., Nadasdy T., Arend L., et al. Treatment of C4d positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 77 (2004) 1399
50. Jordan S.C., Quartel A.W., Czer L.S., et al. Post transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66 (1998) 800
51. Moger V., Ravishankar M.S., Sakhuja V., et al. Intravenous immunoglobulin: a safe option for treatment of steroid-resistant rejection in the presence of infection. Transplantation 77 (2004) 1455
52. Montgomery R.A., Simpkins C.E., Warren D.S., et al. Supplement Anti CD20 rescue therapy for acute antibody mediated rejection in kidney transplant recipients to transplantation O-360. Transplantation 78 Suppl 2 (2004) 140
53. Sidner R.A., Book B.K., Agarwal A., et al. In vivo human B cell subset recovery after in vivo depletion with rituximb, anti human CD20 monoclonal antibodies. Hum Antibodies 13 (2004) 55
54. Aranda Jr. J.M., Scornik J.C., Normann S.J., et al. Anti CD20 monoclonal antibody (Rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 73 (2002) 907
55. Lehnich R.W., Rocha P., Reinsmoen N., et al. Intravenous immunoglobulin and plasmaphresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol 66 (2005) 350
56. Jordan S., Cunningham-Rundies C., and McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety and cost. Am J Transplant 3 (2003) 653
57. Akalin E., and Bromberg J.S. Intravenous Immunoglobulin induction treatment in flow cytometry crossmatch-positive kidney transplant recipients. Hum Immunol 66 (2005) 359
58. Theruvath T.P., Saidman S.L., Mauiyyedi S., et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 72 (2001) 77
59. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70 (2000) 887
60. Bohmig GA, Regele H, Exner M, et al: B C4d-positive acute humoral renal allograft rejection
61. Nojima M., Yoshimito T., Nakao A., et al. Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation. Transplantation 78 Suppl (2004) 282
62. Sun Q., Liu Z.H., Yin G., et al. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroidresistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant 21 (2006) 510
63. Gloorj, Cosio F, Lager DJ, et al: The spectrum of antibody-mediated renal injuries: implications for treatment. 2000 May 28 (Epub ahead of press).
64. Viera C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of antiHLA antibodies in patients awaiting renal transplantation: 1 safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004) 542
65. Cecka J.M., Zhang Q., and Reed E.F. Preformed cytotoxic antibodies in potencial allograft recipients: recent data. Hum Immunol 66 (2005) 343
66. Gloor J.M., DeGoey S.R., Pineda A.A., et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3 (2003) 1017
67. Haas M., Bohmig G.A., Leko-Mohr Z., et al. operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 17 (2002) 1503
68. Sonnenday C.J., Ratner L.E., Zachary A.A., et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 34 (2002) 1614
69. Thielke J., DeChristopher P.J., Sankary H., et al. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc 37 (2005) 643
70. Akalin E., Ames S., Sehgal V., et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry Tor B-cell crossmatch-positive patients. Transplantation 76 (2003) 1444
71. Warren D.S., Zachary A.A., Sonnenday C.J., et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 4 (2004) 561
72. Stegal M.D., Gloor J., Winters J.L., et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346
73. Thielke J., Sankary H.N., DeChristopher P.J., et al. Expanding the donor pool: successful kidney transplant in crossmatch positive patients alter plasmapheresis treatment. Trasplantation 78 (2004) 166
74. Warren D.S., Simpkins C.E., Zachary A.A., et al. Results of kidney transplantation at the time of a positive cytotoxic crossmatch. Trasplantation 78 (2004) 195
75. Gonzalez G, Morales J, Wegmann ME, et al: Renal transplant outcome in hypersensitized patients effect of intravenous immunoglobulin preconditioning associated to thymoglobulin and plasmapheresis induction. Personal communication, 2004
76. Suciu-Foca N., Reed E., D'Agati V.D., et al. Soluble HLA antigens, anti-HLA antibodies and antidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 51 (1991) 593
77. Lee P.C., Terasaki P.I., Takemoto S.K., et al. All chronic rejection failures of kidney transplants preceded by development of HLA antibodies HLA. Transplantation 74 (2002) 1192
78. Piazza A., Poggi E., Borrelli L., et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: post transplant analysis using flow cytometric techniques. Transplantation 71 (2001) 1106
79. Rifle G., Mousson C., Martin L., et al. Donor-specific antibodies in allograft rejection: clinical and experimental data. Transplantation 79 3 Suppl (2005) S14
80. McAlister C.C., Gao Z.H., McAlister V.C., et al. Protective anti-donor IgM production after crossmatch positive liver-kidney transplantation. Liver Transp 10 (2004) 315
81. Diaz J., Sanchez P., Alonso C., et al. Immunological profile of patients awaiting a renal transplant. Clin Transp 18 (2004) 529
82. Heslan J.M., Renaudin K., Thebault P., et al. New evidence for a role of allograft accommodation in long-term tolerance. Transplantation 82 (2006) 1185
83. Cai J., Terasaki P.I., Bloom D.D., et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after campath-1H induction. Transplantation 78 (2004) 919
84. Bian H., Harris P.E., and Reed E.F. Ligation of HLA class 1 molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Int Immunol 10 (1998) 1315
85. Harris P.E., Bian H., and Reed E.F. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 159 (1997) 5697
86. Lepin E.J., Jin Y.P., Barwe S.P., et al. HLA class 1 signal transduction is dependent on Rho GTPase and ROK. Biochem Biophys Res Commun 323 (2004) 213
87. Jin Y.P., Jindra P.T., Gong K.W., et al. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 79 3 Suppl (2005) S19
88. Coupel S., Leboeuf F., Boulday G., et al. RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J Am Soc Nephrol 15 (2004) 2429
89. Watschinger B. Indirect recognition of allo MHC peptides. Potencial role in human transplantation. Nephrol Dial Transpl 14 (1999) 8
90. Sayegh M.H. Why do we reject graft?. Role of indirect allorecognition in graft rejection. Kidney Int 56 (1999) 1967
91. Vella J.P., Spadafora-Ferreira M., Murphy B., et al. Indirect allorecognition of major histocompatibilty complex allopeptides in human renal transplants recipients with chronic graft dysfunction. Transplantion 64 (1997) 795
92. Mhoyan A., Wu G.D., Kakoulidis T.P., et al. Predominant expression of the Th2 response in chronic cardiac allograft rejection. Transpl Int 16 (2003) 464
93. Baker R.J., Hernandez Fuentes M.P., Brookes P.A., et al. Loss of direct and maintenance of indirect alloresponses in renal allogrtf recipients: implications for the pathogenesis of chronic allograft nephropaty. J Immunol 167 (2001) 7199
94. Najarian N., Salama A.D., Fedoseyeva E.V., et al. Enzymelinked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 13 (2002) 252
95. Cornell L.D., and Colvin R.B. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 14 (2005) 229
96. Poduval R.D., Kadambi P.V., Josephson M.A., et al. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation 79 (2005) 228
97. Dickenmann M., Steiger J., Descoeudres B., et al. The fate of C4d positive kidney allografts lacking histological signs of acute rejection. Clin Nephrol 65 (2006) 173
98. Sijpkens Y.W., Joosten S.A., Wong M.C., et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 65 (2004) 2409
99. Lederer S.H., Kluth-Pepper B., Schneeberger H., et al. Impact of humoral alloreactivity early after transplantation on the longterm survival of renal allografts. Kidney Int 59 (2001) 334
100. Feucht H.E. Significance of donor-specific antibodies in acute rejection. Transplant Proc 37 (2005) 3693
101. Baid S., Saidmain S.J., Tolkoff-Rubin N., et al. Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol 13 (2001) 577
102. Bohming G.A., Exner M., Watschinger B., et al. Acute Humoral Renal allograft rejection. Curr Opin Urol 1 (2002) 95